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http://www.biomedcentral.com/1471-2466/14/183RESEARCH ARTICLE Open AccessTransduction of ferret airway epithelia using a
pre-treatment and lentiviral gene vector
Patricia Cmielewski1,2*†, Nigel Farrow1,2,3†, Martin Donnelley1,2,3, Chantelle McIntyre1,3, Jahan Penny-Dimri3,
Tim Kuchel4 and David Parsons1,2,3Abstract
Background: The safety and efficiency of gene therapies for cystic fibrosis (CF) need to be assessed in pre-clinical
models. Using the normal ferret, this study sought to determine whether ferret airway epithelia could be
transduced with a lysophosphatidylcholine (LPC) pre-treatment followed by a VSV-G pseudotyped HIV-1 based
lentiviral (LV) vector, in preparation for future studies in CF ferrets.
Methods: Six normal ferrets (7 -8 weeks old) were treated with a 150 μL LPC pre-treatment, followed one hour later by
a 500 μL LV vector dose containing the LacZ transgene. LacZ gene expression in the conducting airways and lung was
assessed by X-gal staining after 7 days. The presence of transduction in the lung, as well as off-target transduction in
the liver, spleen and gonads, were assessed by qPCR. The levels of LV vector p24 protein bio-distribution in blood sera
were assessed by ELISA at 0, 1, 3, 5 and 7 days.
Results: The dosing protocol was well tolerated. LacZ gene expression was observed en face in the trachea of all
animals. Histology showed that ciliated and basal cells were transduced in the trachea, with rare LacZ transduced
single cells noted in lung. p24 levels was not detectable in the sera of 5 of the 6 animals. The LacZ gene was not
detected in the lung tissue and no off-target transduction was detected by qPCR.
Conclusions: This study shows that ferret airway epithelia are transducible using our unique two-step pre-treatment
and LV vector dosing protocol. We have identified a number of unusual anatomical factors that are likely to influence
the level of transduction that can be achieved in ferret airways. The ability to transduce ferret airway epithelium is a
promising step towards therapeutic LV-CFTR testing in a CF ferret model.
Keywords: Ferret, Lung, Lentivirus, Cystic fibrosis, Gene therapyBackground
Cystic Fibrosis (CF) is an autosomal recessive disorder
caused by a mutational error in the Cystic Fibrosis
Transmembrane Conductance Regulator (CFTR) gene
and its associated protein [1]. The CFTR channel is used
in multiple body systems that utilise epithelial ion gradi-
ents, including but not limited to the pancreas, sweat
glands, gastrointestinal tract and most crucially the lungs
[1]. The resultant dehydration of the airway surface, loss
of cilia movement, and accumulation of highly viscous* Correspondence: patricia.cmielewski@health.sa.gov.au
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article, unless otherwise stated.mucous obstructs the airways and hinders clearance,
thereby promoting bacterial infection [2]. CF airway dis-
ease currently limits the life expectancy of a CF patient
to a predicted median survival estimate of approximately
37 years [3]. Therefore, the successful treatment of CF
airway disease, especially from the earliest stages of life,
is imperative in improving short term and long term sur-
vival of those afflicted with CF.
Gene therapy for a loss-of-function disease like CF in-
volves delivering the appropriate corrective DNA into the
cells of an organism to produce adequate functional pro-
tein to ameliorate the symptoms of that disease. Lentiviral
gene vectors have a number of potential benefits, includ-
ing the ability to transduce both dividing and non-dividing
cells, be pseudotyped with an envelope glycoprotein totral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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carry large genes such as CFTR [5].
Amongst the new generation of CF animal models, the
CFTR knockout ferret exhibits many characteristics hom-
ologous to human CF, including disease of the pancreas,
liver, vas deferens; and variably-penetrant meconium ileus.
The similarities between CF humans and CF ferrets in
their respiratory pathophysiology include defective chlor-
ide transport, submucosal gland fluid secretion, and a pro-
pensity towards lung infection in the early post natal
period [6].
The aim of this study was to expand work done in the
mouse, sheep and marmoset [7-9] and test the ability of our
two-step LPC pre-treatment and lentiviral vector delivery
system to transduce airway cells of the adolescent normal
ferret. The rationale for this work was to prepare for the use
of CF ferrets, by establishing dosing, technical, and analytical
procedures to be applicable for future use in these expensive
and husbandry-intensive disease-specific CF animals.Methods
This study was approved by the Animal Ethics commit-
tees of the Women’s and Children’s Health Network,
South Australia; SA Pathology, South Australia; and the
University of Adelaide, South Australia. Six 7-8 week old
adolescent ferrets Mustela spp (2 male and 4 female,
weight 335 to 460 g) were sourced from a commercial
ferret supplier. Experiments and subsequent monitoring
were performed under specialist veterinarian supervision
at the Gilles Plains South Australian Medical Research
Facility.Gene vector
The nuclear-localised LacZ (LacZnlsco) VSV-G pseudo-
typed HIV-1 based LV vector was produced by transient
transfection of 293T cells using a five plasmid system ac-
cording to previously published protocols [9,10]. The ratio
of plasmids used for all virus preparation (per 245 mm
square plate) was 170 μg of the transgene 1SDmMPSV
LacZnlsco, 3.16 μg of pcDNA3 Tat, 3.16 μg of pHCMVRev,
1 μg pHCMVgagpol, 7.9 μg pHCMV-G.
For purification approximately 1 L of vector supernatant
was collected, and passed through a 0.45 μm filter (What-
man Polydisc AS, GE Healthcare, PA, USA) and then two
MustangQ Acrodiscs (Pall Corporation, NY, USA) con-
nected in series, at a flow rate of 10 ml/min. After loading,
the Acrodiscs were immediately flushed with 30 ml of
PBS. The viral particles were then eluted with 4 ml of 1.5
M NaCl into a sterile tube containing an equal volume of
2% (v/v) mouse serum in H2O. The virus was concen-
trated by ultracentrifugation at 20,000 rpm (53,750 × g)
for 90 minutes at 4°C and then resuspended in 6 × 100 μl
aliquots of 0.9% (w/v) NaCl /0.1% (w/v) mouse serumalbumin and stored at -80°C. A second batch was made in
the same manner and added to the first without thawing.
Virus titre was 4.7 × 108 TU/ml as assayed by qPCR
[11]. The LV vector volume (500 μl) was established based
on body weight linear scale-up from vector deliveries in
mice [7] and comparable dosage protocols in other animal
models, including marmoset and sheep [7,8].
In vitro assessment of vector delivery methods
Pre-treatment and vector were delivered using an ~15 cm
PE delivery cannula (Sterihealth, VIC, Australia) attached
to a syringe, to reach the distal portion of the very long
ferret trachea (~9 cm with 60-70 cartilage rings [12]). To
minimise delivery losses using the long cannula we tested
several vector delivery methods in cell culture. Vector de-
livery was tested in a 10:1 scale system on CHO cells: (a)
as a bolus delivered using a standard 200 μl lab pipette
(control); (b) using the cannula and syringe setup; (c) via
the cannula setup with a 20 μl air chaser [13]; (d) via the
cannula with a 20 μl primer of 0.3% Bovine Serum Albu-
min (BSA, Sigma Aldrich, Cat # A7906), a known LV vec-
tor stabiliser. Note that only the 50 μl LV vector was
delivered to the cells, leaving the 20 μl BSA in the syringe.
CHO cells were seeded at 0.5 × 106 cells/ml in 12 well
plates and incubated at 37°C, 5% CO2 for 3 hours in F12
Hams Media (SAFC Biosciences (USA) Cat # 51655)/10%
(v/v) Fetal Calf Serum (FCS, JRH Biosciences (USA) Cat #
12103)/2 mM glutamine (SAFC Biosciences (USA) Cat #
59202C) and 1:1000 penicillin/streptomycin (pen-strep,
Sigma Aldrich (USA) Cat # P4458). Media was aspirated,
replaced with F12/10% FCS/glutamine/pen-strep supple-
mented with 4 μg/ml polybrene and 2 μg/ml gentamycin
and cells were transduced with the LV-LacZ vector diluted
1:200. A 50 μl aliquot of the LV vector was added to wells
in triplicate, using the four groups described above. Plates
were incubated at 37°C and media was changed at 24
hours and replaced with F12/10% FCS/glutamine for a
further 48 hours. Media was aspirated and cells were
rinsed with PBS and fixed with 0.1% glutaraldehyde in
PBS for 15 minutes on a rocking platform at room
temperature. Cells were washed 3 times in 1 mM MgCl2/
PBS for 10 minutes each and were incubated overnight
with 1:40 dilution of Pre-Xgal (35 mM K3Fe(CN)6, 35 mM
K4Fe(CN)6 1 M MgCl2 : Xgal (40 mg/ml in dimethylfor-
mamamide)) solution at 37°C. The Xgal solution was aspi-
rated, rinsed with PBS twice, and cells were stored in 80%
glycerol. LacZ gene expression was quantified as the num-
ber of blue stained cells averaged from 3 fields of 3.83
cm2/well using light microscopy.
Ferret in vivo pre-treatment and LV dosing
Anaesthesia was induced in each of the ferrets with a s.c.
injection of medetomidine (Domitor, 0.15 mg/kg, Orion
Corporation, Finland) and ketamine (12 mg/kg, Parnell
Cmielewski et al. BMC Pulmonary Medicine 2014, 14:183 Page 3 of 7
http://www.biomedcentral.com/1471-2466/14/183Laboratories, Australia). Animals were intubated with an
endotracheal tube (14 Ga. BD Insyte i.v. cannula, extended
to 15 cm in length with polyethylene tubing) placed so
that the tip was midway between the epiglottis and the
carina. All dosing events were performed with the ferret
held in a prone position, with the head raised at a 20 de-
gree angle. The pre-treatment was a 150 μl of LPC (0.1%
in PBS, Sigma Aldrich L4129). The concentration was de-
rived from studies in mouse models [7,14] and the volume
was scaled up in the same manner as for the gene vector.
The airway pre-treatment was administered through the
PE cannula placed to project ~2 mm past the end of the
endotracheal tube proximal to the carina, via a single
bolus delivery over 10 seconds. Anaesthesia was main-
tained with a second s.c. injection of medetomidine (0.07
mg/kg) and ketamine (6 mg/kg) 30 minutes after pre-
treatment. Lentiviral dosing was performed 1 hour after
pre-treatment. Ferrets were kept intubated and main-
tained in a supine position for the hour after pre-
treatment. A single priming dose of 200 μl BSA was drawn
into the cannula, followed by the 500 μl LV-LacZ (200 μl
diluted with 300 μl PBS) vector to be delivered. The 500 μl
gene vector dose was administered through a cannula
inserted through the endotracheal tube using a single 500
μl bolus delivery over 15 seconds. Animals were kept anaes-
thetised and prone for a further 20 minutes following
dosing. Anaesthetic was reversed using an s.c. injection of
atipamezole (Antisedan, 1.5 mg/kg, Orion Corporation,
Finland). Vital signs were monitored during pre-treatment
and dosing as well as in the post-operative period.Monitoring and tissue harvesting
Body weight and general behaviour were monitored daily,
and blood samples were taken at baseline, 1, 3, 5 and 7 days
after LV dosing. Samples were centrifuged at 13,000 rpm,
with sera stored at -80°C. Animals were humanely killed
one week after dosing by i.p. nembutal overdose (Letha-
barb, >100 mg/kg). The right-most rostral lobe of the lungs
was ligated and the remainder of the lungs was inflation-
fixed in situ for 15 minutes in 2% paraformaldehyde/0.5%
glutaraldehyde (PFA/Glut) in PBS at 4°C and a pressure of
30 cmH2O. The right-most rostral lobe of the lung was
snap-frozen (dry ice), along with samples of liver, spleen
and gonads.LacZ gene expression: Histology
The inflation fixed lung was then excised and submerged
in fresh chilled PFA/Glut overnight, and were processed
for LacZ expression by X-gal staining [7]. The extent of
LacZ gene expression throughout the airways of the lung
was assessed prima facie though examination of gross
transversely-sectioned portions of trachea and lung. Por-
tions that had indications of blue LacZ cell staining wereprepared for routine histological sectioning and stained
with a light eosin counterstain using standard methods.
LV vector presence: p24 ELISA analysis of sera
Blood sera was analysed using an HIV-1 p24 ELISA kit
(Perkin Elmer Life Sciences USA) performed as per manu-
facturer instructions.
LacZ gene presence: qPCR
Tissue samples were processed to extract DNA via the
Wizard SV Genomic DNA Purification System (Promega,
USA, Cat. # A2361) as per manufacturer instructions.
Qualitative PCR (CFX Connect Real-Time PCR, Bio-Rad)
was used to identify the presence of integrated NLS-LacZ
gene, compared to the ferret GAPDH housekeeping gene
[15]. PCR was performed in 8 well strips and specific ampli-
fication was detected using a TaqMan probe master mix
according to the manufacturer’s standard protocol. All sam-
ples were performed in triplicate including a non-template
control under the following cycles: 50°C for 2 min, 95°C for
10 min, 40 cycles of 95°C for 15 sec and 60°C for 1 min.
Cycle thresholds (Ct) for the LacZ gene were normalised
with respect to the housekeeping gene (ΔCt) and copy
numbers per cell of the gene were determined from ΔCt
[8]. The following primers were used: NLS-LacZ forward
GCC ACT TCT TGA TGG ACC ACT T, NLS-LacZ re-
verse CCG CCA CCG ACA TCA TCT, NLS-LacZ probe
FAM-CAC GCG GGC GTA CAT-NFQ, GAPDH forward
CAT CCG GTG TAC CTT TCC TT, GAPDH reverse
CCA GGA AGA CAG GGA GAG TG, and GAPDH probe
GCA CTG CTG CCATGC (GeneWorks, Australia).
Statistical analysis
Results are represented as a mean and standard error of the
mean. Statistical analyses were performed using GraphPad
Prism 6. Statistical significance was set at p = 0.05. Multiple
treatment groups were analyzed by one way analysis of
variance (ANOVA) with Dunnett’s multiple comparisons.
Results
In vitro assessment of vector delivery methods
Figure 1 shows that direct bolus delivery through the 15 cm
cannula produced significant loss of vector titre compared
to a bolus control (p <0.01, ANOVA). Furthermore, using
an air chaser to maximise volume delivery also resulted in a
significantly reduced titre. However, using a liquid BSA pri-
mer was not significantly different to the bolus delivery, so
this method was used for all subsequent animal studies.
Animal health
Based on vital signs monitoring and behavioural obser-
vations throughout the study the airway gene delivery
procedure was well tolerated in all animals.
Figure 1 In vitro assessment of vector delivery methods. In vitro
testing showed significant reductions in titre when the vector was
delivered via the 15 cm PE cannula, with or without an air chaser
(**p <0.01, ANOVA compared to bolus, mean ± SE, n = 3). The
addition of a BSA primer maintained a titre that was not significantly
different to the bolus delivery, so this delivery method was chosen
for all in vivo experiments.
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The level of LacZ gene transfer was assessed en face and
in cross-sections of ferret trachea and lung. All six ferrets
showed small amounts of LacZ gene expression in the tra-
chea, evident as blue-stained cells, with some stained cells
present in the lobular regions of some animals. Figures 2,
3, 4 show typical examples of the patterns and extent of
gene expression in the trachea, including both ciliated
cells and basal cells. Areas of irregular lines or intenseFigure 2 En face tracheal sections. X-Gal stained en face sections of trach
intra-tracheal delivery of 150 μl of 0.1% LPC followed one hour later by 500
at 1 week (20× magnification).patches of blue-stained cell clusters were apparent. The
majority of the LacZ expression was found in the trachea
with very little extending into the lower lung airways and
alveolar regions. Rare scattered LacZ transduced cells
were observed in the lung (see Figure 5), but these were
localised within the upper lobes rather than spread evenly
across all lobes.
LV vector presence: p24 ELISA analysis of sera
The presence of the p24 protein in the blood is an indication
of vector or vector constituents that have passed from the
airway into the vascular space after dosing. p24 protein in
serum was above the threshold of detection in one animal at
day 1. This animal also had the highest level of LacZ trans-
duction, as assessed subjectively during en face examination.
LacZ gene presence: qPCR
The presence of the LacZ gene in the lung, liver, spleen
and gonads was assessed with qualitative PCR (qPCR).
The LacZ gene was not detected in any of the animal tis-
sues assayed.
Discussion
Our in vitro findings were surprising, firstly due to the
magnitude of the losses when using the long cannula, and
secondly that the losses could be prevented using a BSA
primer. Use of an air chaser – as used by other lung gene
vector dosing studies to ensure complete volume delivery
and wide distribution [13] – may not be an appropriate
delivery strategy for use with LV vectors.ea (distal to the cannula tip) from all six ferrets (A-F), following
μl LV-LacZ, demonstrate low levels of patchy LacZ gene transduction
Figure 3 Tracheal histology. Light eosin-stained tracheal cross
section of trachea shows patchy LacZ transduction. Scale bar 100 μm.
Arrows mark LacZ transduced tracheal cells.
Figure 5 Lung histology. In the lung only rare LacZ-stained alveolar
macrophages (arrow) were detected in one or two lobes, in some animals.
Scale bar 10 μm.
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LPC and gene vector delivery system we have developed in
mice [7,9,11,14,16] – and has been ulitised by others in nor-
mal pigs [17] and rabbits [18] – would also transduce the
conducting airway tissues of the normal ferret. The resultsFigure 4 High-power tracheal histology. Light eosin-stained
high-power sections of trachea show LacZ transduction of ciliated and
basal cells (A-C). Arrow in C points to an example of a transduced basal
cell. Scale bar 10 μm.show that the tracheal airway in normal ferrets is transduci-
ble using our lentiviral gene transfer system employing an
LPC pre-treatment. While total LacZ gene expression was
low (but greater than that achieved in sheep [7]) the patchy
pattern of LacZ marker gene expression is similar to that
observed in other animal models [7,8,14].
Importantly, histological examination showed transduc-
tion of both ciliated cells and basal cells. Transduction of
these cell types is important, firstly because airway ciliated
cells are a primary target for a CF gene therapy, with the
aim to restore the ASL depth and allow normal mucocilli-
ary clearance to be driven by properly functioning ciliated
cells. Secondly, the ability to transduce respiratory basal
stem cells enables the corrected CF gene to be passed on
to all of its progeny during normal epithelial cell turnover,
resulting in sustained gene expression.
There are a number of possible reasons why lower than
expected levels of transgene expression were observed in
this study: (1) the viral titre was a approximately 10-fold
lower than previously used; (2) the lung volume of the fer-
ret is not proportional to body size and exceeds the pre-
dicted value by 297% [19], so a linear volume scale up by
weight from mouse may not be appropriate; (3) the tra-
chea is longer than other similarly-sized animals (9 cm
with 60-70 C-shaped tracheal rings [12]).
The upscaling required to produce the large vector
volumes used in this study resulted in a vector titre that
was 10-fold lower than previously used in mouse studies.
Furthermore, the long tracheal length and the consider-
ably larger than expected ratio between lung volume and
body weight/size meant that animals did not receive suf-
ficient gene vector. Overall, this suggests that a linear
scale up by weight from previous mouse studies was in-
sufficient. Results from the analysis of p24 presence in
the blood serum also support the notion that the vector
dose was insufficient.
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way between the epiglottis and the carina so that the bulk
of the pre-treatment and vector dose would be delivered
to the distal portion of the trachea and lung. However,
histological examination showed that there was LacZ ex-
pression along the length of the trachea, indicating signifi-
cant retrograde transduction had occurred (as observed in
mouse fluid-dosing studies [20]). Moreover, this would
affect the volume reaching the distal trachea, lower con-
ducting airways, and lung parenchyma.
Since the ferret trachea is very long (9 cm) and the
lung volume is approximately three-fold larger than pre-
dicted allometrically [12,19], it is likely that the delivered
pre-treatment and vector doses were not sufficient to
produce robust gene expression in the airways. The pre-
treatment and vector volumes may not have acted on
the same regions of airway epithelium, further reducing
the effectiveness of the vector.
Although the bulk of the delivered doses may have
been retained in the trachea, the level of tracheal trans-
duction was still lower than expected. It is conceivable
that the prone positioning resulted in retention of LPC
within the trachea that may have subsequently reduced
the viability of the LV vector. Furthermore, in this orien-
tation vector dose could be more readily lost via fluid
clearance and swallowing.
Conclusion
Despite the low levels of gene expression the outcomes
confirm that the airways of the ferret can be transduced
utilizing our gene delivery protocol employing LPC pre-
treatment and a HIV-1 VSV-G pseudotyped lentiviral
vector. Ciliated and basal cells types can be transduced, po-
tentially providing a basis for both immediate and sustained
transgene expression, respectively. This study has also re-
vealed unique aspects of ferret conducting airways and al-
veolar space anatomy that may have affected the level of
gene expression achieved. Ensuring adequate pre-treatment
and vector volume, maximising the vector titre, attention
to animal orientation during dosing, and determining the
influence of LPC are specific factors to be addressed when
embarking on future studies in normal and CF ferrets. With
optimal dose volumes and vector titre for the ferret lung
anatomy the levels of gene transfer are likely to approach
those in previous mouse studies and provide effective pro-
tocols for future use of lentiviral CFTR gene transfer studies
in CF ferrets.
Abbreviations
CF: Cystic fibrosis; CFTR: Cystic fibrosis transmembrane conductance
regulator; LPC: Lysophosphatidylcholine; LV: Lentiviral; PBS: Phosphate
buffered saline.
Competing interests
The authors declare they have no competing interests.Authors’ contributions
PC, MD and DP designed the study. PC and NF performed the animal
experiments. NF and CM performed the molecular and histological analyses. TK
provided ferret-specific veterinary advice and support, and JPD performed initial
experiment planning including setup of animal procurement. MD, PC, NF and
DP drafted the manuscript. All authors read and approved the final manuscript.
Acknowledgements
Studies supported by the Women’s and Children’s Hospital Foundation and
philanthropic donors via the Cure4CF Foundation (www.cure4cf.org). We
thank Harshavardini Padmanabhan for her assistance with LV vector
preparation, and Professor John F. Englehardt from the University of Iowa for
providing the primers for the ferret GADPH housekeeping gene. MD is
supported by a MS McLeod Fellowship, and NF by a MS McLeod PhD
Scholarship.
Author details
1Respiratory and Sleep Medicine, Women’s and Children’s Hospital, 72 King
William Road, North Adelaide, SA 5006, Australia. 2Centre for Stem Cell
Research, University of Adelaide, Adelaide, SA 5001, Australia. 3School of
Paediatrics and Reproductive Health, University of Adelaide, Adelaide, SA
5001, Australia. 4South Australian Health and Medical Research Institute, Gilles
Plains, SA 5086, Australia.
Received: 19 September 2014 Accepted: 10 November 2014
Published: 21 November 2014
References
1. Thomson A, Harris A: Cystic Fibrosis. 4th edition. New York: Oxford University
Press; 2008.
2. Goor FV, Hadida S, Grootenhuis P: Pharmacological rescue of mutant CFTR
function for the treatment of cystic fibrosis. Curr Top Med Chem 2008, 3:19.
3. Jackson AD, Daly L, Jackson AL, Kelleher C, Marshall BC, Quinton HB,
Fletcher G, Harrington M, Zhou S, McKone EF, Gallagher C, Foley L,
Fitzpatrick P: Validation and use of a parametric model for projecting
cystic fibrosis survivorship beyond observed data: a birth cohort
analysis. Thorax 2011, 66(8):674–679.
4. Potash AE, Wallen TJ, Karp PH, Ernst S, Moninger TO, Gansemer ND, Stoltz
DA, Zabner J, Chang EH: Adenoviral gene transfer corrects the ion
transport defect in the sinus epithelia of a porcine CF model. Mol Ther
2013, 21(5):947–953.
5. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG,
Brody SL, Jaffe HA, Eissa NT, Danel C: Administration of an adenovirus
containing the human CFTR cDNA to the respiratory tract of individuals
with cystic fibrosis. Nat Genet 1994, 8(1):42–51.
6. Sun X, Sui H, Fisher JT, Yan Z, Liu X, Cho HJ, Joo NS, Zhang Y, Zhou W, Yi Y,
Kinyon JM, Lei-Butters DC, Griffin MA, Naumann P, Luo M, Ascher J, Wang K,
Frana T, Wine JJ, Meyerholz DK, Engelhardt JF: Disease phenotype of a fer-
ret CFTR-knockout model of cystic fibrosis. J Clin Invest 2010,
120(9):3149–3160.
7. Liu C, Wong E, Miller D, Smith G, Anson D, Parsons D: Lentiviral airway
gene transfer in lungs of mice and sheep: successes and challenges.
J Gene Med 2010, 12(8):647–658.
8. Farrow N, Miller D, Cmielewski P, Donnelley M, Bright R, Parsons DW:
Airway gene transfer in a non-human primate: lentiviral gene expression
in marmoset lungs. Sci Rep 2013, 3:1287.
9. Cmielewski P, Donnelley M, Parsons DW: Long term therapeutic and
reporter gene expression in lentiviral vector treated cystic fibrosis mice.
J Gene Med 2014, 16(9-10):291–299.
10. Wong ES, McIntyre C, Peters HL, Ranieri E, Anson DS, Fletcher JM:
Correction of methylmalonic aciduria in vivo using a codon-optimized
lentiviral vector. Hum Gene Ther 2014, 25(6):529–538.
11. Kremer KL, Dunning KR, Parsons DW, Anson DS: Gene delivery to airway
epithelial cells in vivo: a direct comparison of apical and basolateral
transduction strategies using pseudotyped lentivirus vectors. J Gene Med
2007, 9(5):362–368.
12. Lloyd M: Ferrets: Health, Husbandry and Diseases. 1st edition. Oxford: Wiley-
Blackwell; 1999.
13. Gau P, Rodriguez S, De Leonardis C, Chen P, Lin DM: Air-assisted intranasal
instillation enhances adenoviral delivery to the olfactory epithelium and
respiratory tract. Gene Ther 2011, 18(5):432–436.
Cmielewski et al. BMC Pulmonary Medicine 2014, 14:183 Page 7 of 7
http://www.biomedcentral.com/1471-2466/14/18314. Stocker AG, Kremer KL, Koldej R, Miller DS, Anson DS, Parsons DW: Single-dose
lentiviral gene transfer for lifetime airway gene expression. J Gene Med
2009, 11(10):861–867.
15. Nakata M, Itou T, Sakai T: Quantitative analysis of inflammatory cytokines
expression in peripheral blood mononuclear cells of the ferret (Mustela
putorius furo) using real-time PCR. Vet Immunol Immunopathol 2009,
130(1–2):88–91.
16. Limberis M, Anson DS, Fuller M, Parsons DW: Recovery of airway cystic
fibrosis transmembrane conductance regulator function in mice with
cystic fibrosis after single-dose lentivirus-mediated gene transfer.
Hum Gene Ther 2002, 13(16):1961–1970.
17. Cao H, Machuca TN, Yeung JC, Wu J, Du K, Duan C, Hashimoto K, Linacre V,
Coates AL, Leung K, Wang J, Yeger H, Cutz E, Liu M, Keshavjee S, Hu J:
Efficient gene delivery to pig airway epithelia and submucosal glands
using helper-dependent adenoviral vectors. Mol Ther Nucleic Acids 2013,
2:e127.
18. Koehler DR, Frndova H, Leung K, Louca E, Palmer D, Ng P, McKerlie C, Cox P,
Coates AL, Hu J: Aerosol delivery of an enhanced helper-dependent
adenovirus formulation to rabbit lung using an intratracheal catheter.
J Gene Med 2005, 7(11):1409–1420.
19. Johnson-Delaney CA, Orosz SE: Ferret respiratory system: clinical anatomy,
physiology, and disease. Vet Clin North Am Exot Anim Pract 2011,
14(2):357–367. vii.
20. Donnelley M, Siu KK, Jamison RA, Parsons DW: Synchrotron phase-contrast
X-ray imaging reveals fluid dosing dynamics for gene transfer into
mouse airways. Gene Ther 2012, 19(1):8–14.
doi:10.1186/1471-2466-14-183
Cite this article as: Cmielewski et al.: Transduction of ferret airway
epithelia using a pre-treatment and lentiviral gene vector. BMC
Pulmonary Medicine 2014 14:183.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
